CN104788421A - 一种治疗呼吸道炎症的厄多司坦化合物及其制备方法 - Google Patents
一种治疗呼吸道炎症的厄多司坦化合物及其制备方法 Download PDFInfo
- Publication number
- CN104788421A CN104788421A CN201510215321.8A CN201510215321A CN104788421A CN 104788421 A CN104788421 A CN 104788421A CN 201510215321 A CN201510215321 A CN 201510215321A CN 104788421 A CN104788421 A CN 104788421A
- Authority
- CN
- China
- Prior art keywords
- erdosteine
- compound according
- erdosteine compound
- compound
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003262 erdosteine Drugs 0.000 title claims abstract description 80
- -1 Erdosteine compound Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 206010068956 Respiratory tract inflammation Diseases 0.000 title abstract 2
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000013078 crystal Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 8
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 7
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
- 238000003756 stirring Methods 0.000 claims description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 17
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 239000012047 saturated solution Substances 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 6
- 230000005260 alpha ray Effects 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010006451 bronchitis Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000120 Artificial Saliva Substances 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 108010028349 saliva Orthana Proteins 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229930186147 Cephalosporin Chemical class 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical class N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610595356.3A CN106146456A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595315.4A CN106187992A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201510215321.8A CN104788421B (zh) | 2015-04-30 | 2015-04-30 | 一种治疗呼吸道炎症的厄多司坦化合物及其制备方法 |
CN201610595340.2A CN106220604A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595361.4A CN106220605A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510215321.8A CN104788421B (zh) | 2015-04-30 | 2015-04-30 | 一种治疗呼吸道炎症的厄多司坦化合物及其制备方法 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610595361.4A Division CN106220605A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595340.2A Division CN106220604A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595315.4A Division CN106187992A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595356.3A Division CN106146456A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104788421A true CN104788421A (zh) | 2015-07-22 |
CN104788421B CN104788421B (zh) | 2016-08-24 |
Family
ID=53553660
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610595356.3A Withdrawn CN106146456A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201510215321.8A Expired - Fee Related CN104788421B (zh) | 2015-04-30 | 2015-04-30 | 一种治疗呼吸道炎症的厄多司坦化合物及其制备方法 |
CN201610595315.4A Withdrawn CN106187992A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595340.2A Withdrawn CN106220604A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595361.4A Withdrawn CN106220605A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610595356.3A Withdrawn CN106146456A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610595315.4A Withdrawn CN106187992A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595340.2A Withdrawn CN106220604A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
CN201610595361.4A Withdrawn CN106220605A (zh) | 2015-04-30 | 2015-04-30 | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (5) | CN106146456A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104983693A (zh) * | 2015-08-13 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗呼吸道感染的药物厄多司坦组合物颗粒剂 |
CN105078901A (zh) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗呼吸系统疾病的药物厄多司坦组合物干混悬剂 |
CN106187991A (zh) * | 2016-07-19 | 2016-12-07 | 山东罗欣药业集团股份有限公司 | 一种治疗呼吸系统疾病的化合物及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202000016816A1 (it) | 2020-07-10 | 2022-01-10 | Edmond Pharma Srl | Composizioni comprendenti composti antiossidanti come coadiuvanti nel trattamento di infezioni virali |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1303065C (zh) * | 2004-05-20 | 2007-03-07 | 江苏豪森药业股份有限公司 | 氨溴索半胱氨酸类似物盐及其制备方法和用途 |
PL2060568T3 (pl) * | 2007-11-16 | 2012-03-30 | Edmond Pharma Srl | Odmiany polimorficzne enancjomerycznie czystej erdosteiny |
CN101941963A (zh) * | 2010-04-22 | 2011-01-12 | 浙江康乐药业股份有限公司 | 一种厄多司坦的合成方法 |
-
2015
- 2015-04-30 CN CN201610595356.3A patent/CN106146456A/zh not_active Withdrawn
- 2015-04-30 CN CN201510215321.8A patent/CN104788421B/zh not_active Expired - Fee Related
- 2015-04-30 CN CN201610595315.4A patent/CN106187992A/zh not_active Withdrawn
- 2015-04-30 CN CN201610595340.2A patent/CN106220604A/zh not_active Withdrawn
- 2015-04-30 CN CN201610595361.4A patent/CN106220605A/zh not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
李飞等: "厄多司坦的合成", 《中国医药工业杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104983693A (zh) * | 2015-08-13 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗呼吸道感染的药物厄多司坦组合物颗粒剂 |
CN105078901A (zh) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗呼吸系统疾病的药物厄多司坦组合物干混悬剂 |
CN106187991A (zh) * | 2016-07-19 | 2016-12-07 | 山东罗欣药业集团股份有限公司 | 一种治疗呼吸系统疾病的化合物及其制备方法 |
CN106187991B (zh) * | 2016-07-19 | 2019-04-30 | 山东罗欣药业集团股份有限公司 | 一种治疗呼吸系统疾病的化合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106146456A (zh) | 2016-11-23 |
CN106187992A (zh) | 2016-12-07 |
CN104788421B (zh) | 2016-08-24 |
CN106220604A (zh) | 2016-12-14 |
CN106220605A (zh) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104788421A (zh) | 一种治疗呼吸道炎症的厄多司坦化合物及其制备方法 | |
CN101095670B (zh) | 木犀草素磷脂复合物及其制备方法和应用 | |
CN108938654A (zh) | 一种白头翁皂苷b4的注射用制剂 | |
WO2021227146A1 (zh) | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 | |
CN110156700A (zh) | 吉非替尼与水杨酸共晶体 | |
JP7007300B2 (ja) | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 | |
WO2010052896A1 (ja) | プロピオン酸フルチカゾンを含む局所投与剤 | |
CN104958318A (zh) | 一种治疗感染性疾病的药物舒巴坦钠组合物 | |
CN102643255A (zh) | 一种炎琥宁化合物 | |
CN102796078A (zh) | 一种泮托拉唑化合物、制备方法及其药物制剂 | |
CN104873495A (zh) | 一种治疗呼吸道炎症的厄多司坦组合物 | |
CN104922080A (zh) | 治疗消化系统疾病的药物艾普拉唑钠冻干粉针剂组合物 | |
CN104844624B (zh) | 一种头孢哌酮钠舒巴坦钠共晶与组合物及其制备方法 | |
CN102988402A (zh) | 一种含有环磷腺苷化合物药物组合物及其制备方法 | |
CN105232473A (zh) | 一种治疗呼吸道感染的药物厄多司坦组合物颗粒剂 | |
CN106176642B (zh) | 一种治疗呼吸系统疾病的分散片剂及其制备方法 | |
CN104983693A (zh) | 一种治疗呼吸道感染的药物厄多司坦组合物颗粒剂 | |
CN102793929B (zh) | 一种制备稳定非晶态药物制剂的方法 | |
CN103040737B (zh) | 一种含有兰索拉唑化合物的药物组合物及其制备方法 | |
CN105640895A (zh) | 一种头孢羟氨苄颗粒制剂及其制备方法 | |
CN104721154A (zh) | 注射用谷氨酸诺氟沙星冷冻干燥粉针剂药物组合物 | |
CN104829467A (zh) | 盐酸氨溴索二水化合物 | |
CN106187991B (zh) | 一种治疗呼吸系统疾病的化合物及其制备方法 | |
CN105232445A (zh) | 一种治疗呼吸系统疾病的药物厄多司坦组合物干混悬剂 | |
CN105078901A (zh) | 一种治疗呼吸系统疾病的药物厄多司坦组合物干混悬剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160712 Address after: 264000 Shandong city of Yantai Province Economic and Technological Development Zone odd Road No. 2, Room 102 on the right side of the vertical snow garden Simon Applicant after: YANTAI LANYANGZHICAO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. Applicant after: Wang Yumei Address before: 276017 Linyi hi tech Industrial Development Zone, Shandong science and Technology Park A321 Di Di science and Technology Information Service Center Applicant before: Miao Yiwen |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yumei Inventor after: Li Zhijuan Inventor after: Wang Xiaoye Inventor before: Wang Yumei |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161012 Address after: 264000 Shandong Province, Yantai City Economic and Technological Development Zone Industry odd Road No. 2, Room 102 on the right side of the vertical snow garden Simon Patentee after: YANTAI LANYANGZHICAO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. Address before: 264000 Shandong city of Yantai Province Economic and Technological Development Zone odd Road No. 2, Room 102 on the right side of the vertical snow garden Simon Patentee before: YANTAI LANYANGZHICAO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. Patentee before: Wang Yumei |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yumei Inventor after: Li Zhijuan Inventor after: Wang Xiaoye Inventor after: Sun Zongwen Inventor after: Xu Qiwen Inventor after: Li Gongyan Inventor after: Gong Piju Inventor before: Wang Yumei Inventor before: Li Zhijuan Inventor before: Wang Xiaoye |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170524 Address after: 10 village, four floor village, cooperative Town, Qidong City, Jiangsu, Nantong 226200 Patentee after: Nantong Kai Wunong Products Co. Ltd. Address before: 264000 Shandong Province, Yantai City Economic and Technological Development Zone Industry odd Road No. 2, Room 102 on the right side of the vertical snow garden Simon Patentee before: YANTAI LANYANGZHICAO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yumei Inventor after: Li Zhijuan Inventor after: Wang Xiaoye Inventor after: Sun Zongwen Inventor after: Xu Qiwen Inventor after: Li Gongyan Inventor after: Gong Piju Inventor after: Liu Huantao Inventor before: Wang Yumei Inventor before: Li Zhijuan Inventor before: Wang Xiaoye Inventor before: Sun Zongwen Inventor before: Xu Qiwen Inventor before: Li Gongyan Inventor before: Gong Piju |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20190430 |